For All The Latest Medical News, Health News, Research News, COVID-19 News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Cardiology News, Epigenetic News, Cancer News, Doctor News, Hospital News

✖
 ENGLISH
 ENGLISH  THAI
BREAKING NEWS
Source: Thailand Medical News  Nov 27, 2019  4 years, 11 months, 3 weeks, 5 days, 15 hours, 51 minutes ago

Phase Three Clinical Trials Shows That Bempedoic Acid Significantly Reduces LDL-Cholesterol And Also Haemoglobin A1c

Pharma News
Phase Three Clinical Trials Shows That Bempedoic Acid Significantly Reduces LDL-Cholesterol And Also Haemoglobin A1c
Source: Thailand Medical News  Nov 27, 2019  4 years, 11 months, 3 weeks, 5 days, 15 hours, 51 minutes ago
  • Bempedoic acid is an oral, once-daily ATP citrate lyase (ACL) inhibitor that reduces cholesterol synthesis in the liver and is currently undergoing regulatory review
  • Bempedoic acid lowered LDL-Cholesterol by 17% on top of maximally-tolerated statin therapy at 12 weeks, and the effect was durable through 52 weeks1
  • Overall adverse events in the bempedoic acid treatment arm were comparable to placebo over 52 weeks1
Pharma giant, Daiichi Sankyo Europe GmbH announced the publication of results from the Phase 3 CLEAR Wisdom trial in the Journal of the American Medical Association (JAMA).1 Bempedoic acid is currently undergoing review for marketing authorisation by the European Medicines Agency (EMA) and by the United States Food and Drug Administration (FDA).



The CLEAR Wisdom, is a Phase 3, double-blind, randomised trial, evaluated the efficacy, long-term safety and tolerability of bempedoic acid 180 mg versus placebo in 779 patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolaemia (HeFH) inadequately controlled with current lipid-modifying therapies, added on to maximally-tolerated statin therapy, which may mean no statin at all.1

The  findings in the JAMA publication includes results for the primary efficacy endpoint of low-density lipoprotein cholesterol (LDL-C) lowering at 12 weeks and key secondary endpoints of safety and tolerability over 52 weeks. The publication reports that bempedoic acid:1
  • significantly lowered LDL-C by 17% on background maximally-tolerated statin therapy at 12 weeks, with nearly all patients (85%, 444/522 ) on moderate- or high-intensity statins, and the effect was durable through 52 weeks;
  • significantly lowered high-sensitivity C-reactive protein (hsCRP), an important marker of the underlying inflammation associated with cardiovascular disease, by 19%, and the effect was durable through 52 weeks;
  • showed no worsening of haemoglobin A1c (HbA1c) (- 0.21% vs. placebo) in patients with diabetes at 12 weeks;
  • showed overall adverse event rates comparable with placebo (bempedoic acid 70% 366/522 vs. placebo 71% 182/257) at 52 weeks, and the proportion of patients with reported serious adverse events was similar compared with placebo (bempedoic acid 20% 106/522 vs. placebo 19% 48/257) at 52 weeks;
  • showed adjudicated three-component major adverse cardiac event rates of 2.7% (14/522) with bempedoic acid and 4.7% (12/257) with placebo.
 
Dr Anne C. Goldberg MD, FACP, FAHA, FNLA, Professor of Medicine, Division of Endocrinology, Metabolism and Lipid Research at Washington University, St. Louis and lead study author told Thailand Medical News, “The CLEAR Wisdom trial demonstrated that bempedoic acid< ;/strong> provided additional LDL-C lowering in patients on background maximally-tolerated statin therapy and had an overall adverse event profile that was comparable to placebo.These results are consistent with the results reported from the largest long-term Phase 3 study of bempedoic acid, Study 1 or CLEAR Harmony, which were published earlier this year in the New England Journal of Medicine. Results across the Phase 3 development programme show that bempedoic acid has the potential to be a treatment option for high-risk patients who require additional LDL-C lowering.”

Dr Wolfgang Zierhut, MD, Head of Antithrombotic and Cardiovascular Medical Affairs Department at Daiichi Sankyo Europe commented, “We believe that bempedoic acid will address an important unmet need for patients who require additional LDL-C lowering and are not reaching their goals with existing oral lipid lowering therapies. Many patients remain at high risk of a cardiovascular event and need additional treatment options to achieve LDL-C goals. This is even more pertinent given that the latest guidelines suggest even lower LDL-C goals to provide optimal protection.”

Background of Global Pivotal Phase 3 Study 2 (1002-047, also known as CLEAR Wisdom)

The 52-week, global, pivotal Phase 3 randomised, double-blind, placebo-controlled, multi-centre study evaluated the efficacy and safety of bempedoic acid 180 mg/day versus placebo. The study was conducted at 86 sites in North America and Europe. A total of 779 patients were randomised 2:1 to receive bempedoic acid or placebo. The primary efficacy objective was to assess the 12-week LDL-C lowering efficacy of bempedoic acid versus placebo. Secondary objectives included evaluating the safety and tolerability of bempedoic acid versus placebo, the 24-week and 52-week LDL-C lowering efficacy of bempedoic acid versus placebo, and bempedoic acid’s effects on other risk markers after 12 weeks of treatment, including hsCRP and HbA1c, versus placebo.

Bempedoic acid is an oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces cholesterol synthesis in the liver and thereby lowers circulating LDL-C levels.2,3 It is intended for patients with hypercholesterolaemia and/or at high risk of atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering despite maximally-tolerated statin therapy.

Bempedoic acid has a unique, innovative mode of action, which is complimentary to other lipid-lowering therapies, such as statins.4 Due to its liver-specific mode of action, bempedoic acid has a reduced potential to induce the muscle-related side-effects commonly associated with statin therapy and provide additional LDL-C lowering on top of statin monotherapy in clinical trials.3

Bempedoic acid (180 mg) and the bempedoic acid / ezetimibe fixed dose combination tablet (180 mg/10 mg) are currently under review by the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use and the U.S. Food and Drug Administration for LDL-C lowering in patients who are not yet at their target LDL-C level. Daiichi Sankyo Europe licensed exclusive commercialisation rights to these products in the European Economic Area and Switzerland from Esperion. Approval decisions are expected during the first half of 2020.

References:
1 Goldberg AC, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease. The CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019;322(18):1780-1788. doi:10.1001/jama.2019.16585.
2 Ray KK, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019;380:1022–32.
3 Ballantyne CM, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis.2018;277:195–203.
4 Laufs U, et al. Efficacy and Safety of Bempedoic Acid in Patients with Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc. 2019;8(7):e011662.
 

MOST READ

Nov 08, 2024  16 days ago
Nikhil Prasad
COVID-19 and the Hidden Threat of Cytomegalovirus (CMV) Reactivation
Nov 05, 2024  19 days ago
Nikhil Prasad
Study Reveals That COVID-19 Alters Key Human Genes
Oct 07, 2024  2 months ago
Nikhil Prasad
Study reveals the SARS-CoV-2 spike protein interacts with over 60,000 host proteins and may trigger carcinogenesis!
Aug 08, 2024  4 months ago
Nikhil Prasad
COVID-19 induced endothelial dysfunction will lead to a pandemic of chronic kidney and cardiovascular diseases
Aug 04, 2024  4 months ago
Nikhil Prasad
COVID-19's unexpected impact - Rising orofacial pain among infected individuals
Jul 25, 2024  4 months ago
Nikhil Prasad
Murine study shows how COVID-19 increases risk for stroke
Jul 24, 2024  4 months ago
Nikhil Prasad
COVID-19 can cause Osteomyelitis of the jaw
Jul 22, 2024  4 months ago
Nikhil Prasad
COVID-19 causes Blood DNA Methylation, a potential biomarker for Long COVID severity
Jul 22, 2024  4 months ago
Nikhil Prasad
Doctors from Turkey warns that children exposed to SARS-CoV-2 are at risk of acute kidney injury
Jul 08, 2024  5 months ago
Nikhil Prasad
Unknown To Many Including Doctors, COVID-19 Causes Parsonage Turner Syndrome
Jun 26, 2024  5 months ago
Nikhil Prasad
BREAKING! Mild COVID Causes A Slow Progressing Eye Debilitating Condition That Most Are Not Even Aware Of Till It's Too Late!
Jun 24, 2024  5 months ago
Nikhil Prasad
COVID-19's Hidden Impact on Eyes: Unveiling Rare Retinal Conditions
Jun 23, 2024  5 months ago
Nikhil Prasad
Somnolence And Shingles Seems To Be New Symptom/Manifestation Of COVID-19 KP.3 And LB.1 Infections!
Jun 22, 2024  5 months ago
Nikhil Prasad
Herbs And Phytochemicals: Fermented Codonopsis lanceolata Root Extract Shows Promise Against Influenza A Virus
Jun 12, 2024  5 months ago
Nikhil Prasad
Most Long COVID Patients Likely To Develop New Onset Psychiatric Disease!
Mar 12, 2024  9 months ago
Nikhil Prasad
Mild Or Moderate COVID-19 Causes Accelerated Brain Aging Especially In Young To Early Middle-Aged Adults!
Mar 10, 2024  9 months ago
Nikhil Prasad
Six Percent Of All Post-COVID Patients Who Have Hip Discomfort Likely To Have Developed Avascular Necrosis Of The Femoral Head!
Mar 05, 2024  9 months ago
Nikhil Prasad
Austrian Scientists Claim That High-Density Lipoproteins Can Be Used As Antivirals Against COVID-19 Infections
Feb 20, 2024  9 months ago
Nikhil Prasad
New Measles Variant That Can Evade Current Diagnostics Identified In Italy! More New Strains To Be Announced Soon!
Jan 02, 2024  11 months ago
Nikhil Prasad
BREAKING COVID-19 News! Study Claims That Omicron Infections Can Lead To Acute Primary Angle Closure And Also Primary Angle Closure Glaucoma!
Dec 16, 2023  11 months ago
Nikhil Prasad
BREAKING COVID-19 News! Australian Scientists Discover A microRNA Called CoV2-miR-O8 That Is Encoded By SARS-CoV-2 And Is Possibly Pathogenetic!
Dec 15, 2023  11 months ago
Nikhil Prasad
COVID-19 News: Foods Rich In XeSiAs-Neu5Gc Contributes To Xenosialylation That Causes Worse Outcomes In SARS-CoV-2 Infections And Vaccination!
Oct 23, 2023  1 year ago
Nikhil Prasad
COVID-19 News: SARS-CoV-2 Is Likely An Oncogenic Virus That Will Cause Lung, Colorectal, Oral, Pancreatic And Breast Cancers In The Long Term!
Jun 29, 2023  1 year ago
Medical News - SARS-CoV-2 - IGF2BP1
BREAKING! Scientists Warns That SARS-CoV-2 Also Interacts With IGF2BP1- An Oncofetal RNA-Binding Protein That Typically Fuels Tumor Virus Propagation!
Jun 10, 2023  1 year ago
COVID-19 News - DNA Methylation - Asymptomatic SARS-CoV-2 Infections
BREAKING NEWS! Even Asymptomatic SARS-CoV-2 Infections Cause DNA Methylation And Epigenetic Changes, Leading to Immune Dysregulation!
May 13, 2023  2 years ago
COVID-19 News - Viral Peristence - Long COVID
There Is No Such Thing As Long COVID! SARS-CoV-2 Exposure Causes Persistent Infections Along With Continuous Presence Of Short Viral RNAs (svRNAs)!
Feb 07, 2023  2 years ago
COVID-19 News - Breast Cancer
BREAKING! COVID-19 News: SARS-CoV-2 Infections Lead To Increased Risk Of Breast Cancer, Recurrence Of Breast Cancer And Also Breast Cancer Metastasis!
Nov 29, 2022  2 years ago
COVID-19 News - D-Alanine Supplements Prevents COVID-19 Severity
BREAKING COVID-19 News: Japanese Scientists Find That Supplementation With The Amino Acid D-Alanine Can Help Prevent And Treat COVID-19 Severity!
Sep 28, 2022  2 years ago
Source: Medical News - SARS-CoV-2 Reinfections - Omicron
Study Validates Previous Findings That SARS-CoV-2 Reinfections Are Now Occurring At Shorter Intervals. Current CDC and ECDC Reinfection Definitions Are Obsolete!
Aug 04, 2022  2 years ago
Source: Medical News - SARS-CoV-2 & Cancer
BREAKING! Study Finds That Cancer Causing Genes Are Upregulated In SARS-CoV-2 Infected Individuals!
Jun 27, 2022  2 years ago
Source: Medical News -SARS-CoV-2 Reduces Human Life Spans
BREAKING! Hypothesis That Majority Exposed To SARS-CoV-2 Will Have Shortened Lifespans Validated By Study Showing NSP2 Impairs Human 4EHP-GIGYF2 Complex!
Dec 25, 2021  3 years ago
Source: SARS-CoV-2 Viral Persistence
BREAKING! U.S. NIH Study Shockingly Reveals SARS-CoV-2 Viral Persistence Throughout Human Body And In The Brain Even In Those Who Were Asymptomatic!
Nov 18, 2021  3 years ago
Source: SARS-CoV-2-Cancer
BREAKING! New International Study Warns That SARS-CoV-2 Infections Will Lead To Cancers Especially Colorectal Cancers Due to Disruption In Autophagy!
Nov 13, 2020  4 years ago
Source: COVID-19 Genetics
BREAKING! COVID-19 Genetics: Yale Scientist Identify Eight ‘Super’ Genetic Variants In White People That Increases COVID-19 Death Risk!
Nov 05, 2020  4 years ago
Source: Ozone Water-COVID-19
Japanese Study Shows That Ozone Water Rapidly Inactivates SARS-Cov-2 Coronavirus, Making It An Ideal COVID-19 Disinfectant And Sanitizer
Sep 30, 2020  4 years ago
Source: BREAKING NEWS
BREAKING NEWS! COVID-19 Study Reveals That SARS-CoV-2 Uses CD4 Cells To Infect T-helper Lymphocytes. COVID-19 A Potent Version Of Airborne HIV?

FROM MEDICAL TIPS

LATEST ON PHARMA NEWS

World COVID-19 News
COVID-19 Diagnostics
COVID-19 Drugs
COVID-19 Supplements
COVID-19 Herbs
COVID-19 Disinfectants
COVID-19 Mutations
COVID-19 Research
COVID News
Long COVID
COVID-19 Vaccines
COVID-19 Clinical Care
Medical Press Releases
Medical Innovations & Startups
AI in Medicine
Thailand Biotech News
Medical Spheres Bulletins
Medical White Papers
Medical Packages
Medical Tips
Medical Support Groups
Medical Tourism
TNM Aristrocrat Club
Medical Journals
Thai Herbal Products
TMN Medical Mart
Wellness Centers
Rehab Centers
Medsiam App